A Phase 2 interventional study of RAD1901 and RAD1901 in Hot Flashes, sponsored by Radius Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to female participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-09-26.
Sponsored by Radius Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.
Among the 193 studies in Hot Flashes with a site in United States, this one is the 81st largest by enrollment of the 180 interventional ones that give a count, is one of 8 that started in 2009, is one of 41 in phase 2, and was the 75th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+ · Men only
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
India Glycols Ltd · Sites in United States
Ages 45–60 · Women only
University of Kentucky · Sites in United States
Ages 18–99
University of Virginia · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 48 · Phase 3 40 · Phase 4 14
First in 1997; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 84 across the 180 interventional studies, 74 across the 6 observational. Of the 156 that completed or were terminated, 67 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 193 have an industry lead sponsor. The 10 most frequent:
Radius Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
Radius Pharmaceuticals, Inc. has 2 studies filed under Hot Flashes — fewer than ten, so there is no comparison to draw.
14 of the studies in Hot Flashes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07903480Primal Harvest, LLCA Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being | 2026-12 |
| NCT05193968Mayo ClinicHot Flashes and Neurovascular Function in Women | 2026-12 |
| NCT07861295Vidya USA CorporationSatavari and Ashoka for Menopause (SAM) Study | 2026-12-01 |
| NCT07335224Inova Health Care ServicesMen With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture | 2026-12-31 |
| NCT06972875University of VermontFezolinetant for Treating Hot Flashes in Men With Prostate Cancer | 2027-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 193 studies in Hot Flashes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether RAD1901 is effective in decreasing hot flashes in postmenopausal women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral once a day for 28 days
Drug: RAD1901
Oral once a day for 28 days
Drug: RAD1901
Oral once a day for 28 days
Drug: RAD1901
Oral once a day for 28 days
Drug: RAD1901
Oral once a day for 28 days
Drug: Placebo
Percent Change in Frequency of Hot Flashes Over Time
Percent change of moderate and severe hot flash frequency at 4 weeks compared to baseline using weekly Subject diary data, in the intent-to-treat population.
Time frame: Week 4 minus baseline week
Percent Change in Composite Score Over Time
Percent change in composite score (frequency x severity) of hot flashes (Mild=1, Moderate=2, Severe=3) at 4 weeks compared to baseline, in the intent-to-treat population.
Time frame: Week 4 minus baseline week
Determine the Effects of RAD1901 on Follicular Stimulating Hormone (FSH) Over Time.
Percent change in FSH at Day 29 compared to baseline, in the intent-to-treat population.
Time frame: Day 29 minus baseline
Determine the Effects of RAD1901 on Luteinizing Hormone (LH) Over Time.
Percent change in LH levels at Day 29 compared to baseline, in the intent-to-treat population.
Time frame: Day 29 minus baseline
| Milestone | RAD1901 10 mg | RAD1901 25 mg | RAD1901 50 mg | RAD1901 100 mg | Placebo |
|---|---|---|---|---|---|
| Started | 22 | 20 | 21 | 18 | 19 |
| Completed | 20 | 18 | 18 | 16 | 17 |
| Not completed | 2 | 2 | 3 | 2 | 2 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Inability to complete study procedures | 1 | 0 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Personal reason | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Prohibited medication | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
Percent change of moderate and severe hot flash frequency at 4 weeks compared to baseline using weekly Subject diary data, in the intent-to-treat population.
| Percent change from baseline | RAD1901 10 mg | RAD1901 25 mg | RAD1901 50 mg | RAD1901 100 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change in Frequency of Hot Flashes Over Time | -77.2 ± 20.43 | -51.8 ± 45.02 | -53.8 ± 39.16 | -67.0 ± 33.85 | -54.1 ± 37.72 |
Percent change in FSH at Day 29 compared to baseline, in the intent-to-treat population.
| Percent change from baseline | RAD1901 10 mg | RAD1901 25 mg | RAD1901 50 mg | RAD1901 100 mg | Placebo |
|---|---|---|---|---|---|
| Determine the Effects of RAD1901 on Follicular Stimulating Hormone (FSH) Over Time. | 4.24 ± 34.077 | -6.56 ± 13.933 | -4.42 ± 24.381 | -3.26 ± 11.373 | 8.67 ± 62.175 |
Percent change in LH levels at Day 29 compared to baseline, in the intent-to-treat population.
| Percent change from baseline | RAD1901 10 mg | RAD1901 25 mg | RAD1901 50 mg | RAD1901 100 mg | Placebo |
|---|---|---|---|---|---|
| Determine the Effects of RAD1901 on Luteinizing Hormone (LH) Over Time. | -12.81 ± 27.551 | -0.19 ± 19.573 | -10.94 ± 22.609 | 3.57 ± 22.392 | 6.70 ± 36.270 |
Percent change in composite score (frequency x severity) of hot flashes (Mild=1, Moderate=2, Severe=3) at 4 weeks compared to baseline, in the intent-to-treat population.
| Percent change from baseline | RAD1901 10 mg | RAD1901 25 mg | RAD1901 50 mg | RAD1901 100 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change in Composite Score Over Time | -75.65 ± 18.655 | -55.48 ± 39.442 | -48.78 ± 39.806 | -66.21 ± 33.226 | -55.80 ± 35.523 |
Collected over Adverse events were collected for 2 months during this study; from start of treatment to the end-of-treatment visit (Day 29) and 30 days after end-of-treatment visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RAD1901 10 mg | — | 0/22 (0%) | 16/22 (72.7%) |
| RAD1901 25 mg | — | 0/20 (0%) | 14/20 (70%) |
| RAD1901 50 mg | — | 0/21 (0%) | 14/21 (66.7%) |
| RAD1901 100 mg | — | 0/18 (0%) | 14/18 (77.8%) |
| Placebo | — | 0/19 (0%) | 11/19 (57.9%) |
| Event | RAD1901 10 mg | RAD1901 25 mg | RAD1901 50 mg | RAD1901 100 mg | Placebo |
|---|---|---|---|---|---|
| InfluenzaInfections and infestations | 2/22 | 4/20 | 2/21 | 1/18 | 0/19 |
| HeadacheNervous system disorders | 4/22 | 2/20 | 2/21 | 2/18 | 2/19 |
| GastritisGastrointestinal disorders | 3/22 | 1/20 | 1/21 | 2/18 | 0/19 |
| HypocholesterolaemiaMetabolism and nutrition disorders | 3/22 | 1/20 | 0/21 | 0/18 | 0/19 |
| DyspepsiaGastrointestinal disorders | 0/22 | 0/20 | 1/21 | 2/18 | 0/19 |
| SomnolenceNervous system disorders | 0/22 | 0/20 | 0/21 | 0/18 | 2/19 |
| HypertensionVascular disorders | 0/22 | 0/20 | 1/21 | 1/18 | 2/19 |
| HyperchlorhydriaGastrointestinal disorders | 0/22 | 2/20 | 0/21 | 0/18 | 1/19 |
| Urinary Tract InfectionInfections and infestations | 1/22 | 2/20 | 1/21 | 0/18 | 0/19 |
| AnxietyPsychiatric disorders | 0/22 | 2/20 | 0/21 | 0/18 | 0/19 |
| Age, Continuous(years) | RAD1901 10 mg | RAD1901 25 mg | RAD1901 50 mg | RAD1901 100 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 53.5 ± 5.74 | 55.2 ± 7.74 | 53.7 ± 5.68 | 55.7 ± 6.45 | 53.8 ± 5.74 | 54.3 ± 6.24 |
| Sex: Female, Male(Participants) | RAD1901 10 mg | RAD1901 25 mg | RAD1901 50 mg | RAD1901 100 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 22 | 20 | 21 | 18 | 19 | 100 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | RAD1901 10 mg | RAD1901 25 mg | RAD1901 50 mg | RAD1901 100 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 22 | 20 | 21 | 18 | 19 | 100 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Mar 2009, a primary completion of Jan 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elacestrant
Radius Pharmaceuticals, Inc.